ストックスクリーナーアプリを入手
18.23
5.89%
-1.14
アフターアワーズ：
18.23
Seaport Therapeutics Inc (SPTX) 最新ニュース
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart - mexc.co
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Insider Stock Purchases: June 24, 2026 - Moomoo
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - marketscreener.com
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com India
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
Seaport Therapeutics reports phase 1 data for anxiety drug By Investing.com - Investing.com South Africa
Seaport Therapeutics 1Q 2026: Net loss $(25.4M), EPS $(10.34) — 10-Q Summary - TradingView
Seaport Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
SPTX: Q1 2026 net loss rose to $25.4M; cash and investments total $212.6M post-IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, vs. FactSet Est of $10.64 Loss - marketscreener.com
Seaport Therapeutics reports phase 1 data for anxiety drug - Investing.com
SPTX: Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment - TradingView
Seaport Therapeutics reports Q1 2026 net loss of $25.4M, cash $212.6M before $260M IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, Vs. FactSet Est of $10.64 Loss - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers - TradingView
Press Release: Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - The Joplin Globe
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):